leisure time -WSS

leisure time

author：comprehensive 2025-09-29 20:51:10 - browse：78948

Japanese drugmaker Eisai said Tuesday that Ivan Cheung, chairman of its U.S. operations and global head of its Alzheimer’s disease unit, will retire at the end of the month. The surprise announcement comes just days after Eisai won final approval in the U.S. for its Alzheimer’s drug Leqembi.

Cheung will be replaced in his capacity as head of the Alzheimer’s unit by his brother-in-law Keisuke Naito, 34, who is currently chief ecosystem officer and chief strategy officer. He is also the son of Eisai CEO Haruo Naito.

Tatsuyuki Yasuno, current chief financial officer, will replace Cheung as head of Eisai’s U.S. unit.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Readout Newsletter: Merck, Vertex, and Viking updates

WSS

Covid vaccine financial winners and losers, from Pfizer to Novavax

Covid silver lining: Unprecedented look at human immune system

Readout Newsletter: Cardior, Regeneron, Nuvation, Dyne and more

First Opinion on colorectal cancer screening: letter and response

Abortion pill Supreme Court ruling could impact entire drug industry

Merck drug for rare lung condition set for approval in U.S.

focus

leisure time

hotspot

Activists slam private health insurers over coverage restrictions

Researchers test human milk's ability to repair gut microbiome

Virginia high school admissions case could be legal follow

Oprah kicked off a national conversation on obesity. Let's have it

Continuity nursing helped my family in our darkest PICU moments

Mass General Brigham physicians react to latest merger step

Dobbs anniversary: the lost opportunity of abortion as health care

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Peter Hotez and the public health issue of online harassment

Washington mulls new rules to avert another Change Healthcare

explore

First Opinion on colorectal cancer screening: letter and response

Insurer loopholes limit power of law against surprise medical bills

Study says nonprofit hospitals fall short in charity care spending

Scientists uncover potential path to treating deadly childhood tumor

First Opinion on colorectal cancer screening: letter and response

Oral obesity drug from Viking Therapeutics hits key early target

focus

hotspot

hotspot

hotspot